Skip Nav Destination
Issues
1 September 2008
-
Cover Image
Cover Image
PKD1 (green), β-catenin (red), and p230 (blue) expression and co-localization in Bryostatin 1 treated C4-2-PKD1-GFP prostate cancer cells. Bryostatin 1 treated C4-2-PKD1-GFP cells were transfected with a PKD1 silencing or nontargeted siRNA and stained for β-catenin and p230 antibodies. Confocal images show co-expression and co-localization of PKD1 (green), β-catenin (red), and p230 (blue). In nontargeted siRNA treated cells β-catenin shows strong membrane localization and perinuclear localization in control siRNA transfected cells (left). However, inhibition of PKD1-GFP expression through PKD1 targeted siRNA resulted into punctuate membrane staining and loss of perinuclear β-catenin staining (right). For details, see Jaggi et al., in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Review
Research Articles: Therapeutics, Targets, and Development
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
Yonglei Shang; Yifan Mao; Jennifer Batson; Suzie J. Scales; Gail Phillips; Mark R. Lackner; Klara Totpal; Simon Williams; Jihong Yang; Zhijun Tang; Zora Modrusan; Christine Tan; Wei-Ching Liang; Siao Ping Tsai; Alexander Vanderbilt; Kenji Kozuka; Klaus Hoeflich; Janet Tien; Sarajane Ross; Congfen Li; Sang Hoon Lee; An Song; Yan Wu; Jean-Philippe Stephan; Avi Ashkenazi; Jiping Zha
Discovery of a novel class of AKT pleckstrin homology domain inhibitors
Daruka Mahadevan; Garth Powis; Eugene A. Mash; Benjamin George; Vijay M. Gokhale; Shuxing Zhang; Kishore Shakalya; Lei Du-Cuny; Margareta Berggren; M. Ahad Ali; Umasish Jana; Nathan Ihle; Sylvestor Moses; Chloe Franklin; Satya Narayan; Nikhil Shirahatti; Emmanuelle J. Meuillet
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95
Margaret A. Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P. Hagan; Adly Yacoub; David T. Curiel; Paul B. Fisher; Steven Grant; Paul Dent
Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism
Matthew B. Rettig; David Heber; Jiabin An; Navindra P. Seeram; Jian Y. Rao; Huiren Liu; Tobias Klatte; Arie Belldegrun; Aune Moro; Susanne M. Henning; Deqiong Mo; William J. Aronson; Allan Pantuck
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer
Georg Feldmann; Volker Fendrich; Karen McGovern; Djahida Bedja; Savita Bisht; Hector Alvarez; Jan-Bart M. Koorstra; Nils Habbe; Collins Karikari; Michael Mullendore; Kathleen L. Gabrielson; Rajni Sharma; William Matsui; Anirban Maitra
Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways
Kiyoshi Yamaguchi; Maria Cekanova; Michael F. McEntee; Joo-Heon Yoon; Susan M. Fischer; Ingrid B. Renes; Isabelle Van Seuningen; Seung Joon Baek
Glucose-regulated protein 78 regulates multiple malignant phenotypes in head and neck cancer and may serve as a molecular target of therapeutic intervention
Ching-Chi Chiu; Chien-Yu Lin; Li-Yu Lee; Yin-Ju Chen; Ting-Fang Kuo; Joseph Tung-Chieh Chang; Chun-Ta Liao; Hung-Ming Wang; Tzu-Chen Yen; Chia-Rui Shen; Shuen-Kuei Liao; Ann-Joy Cheng
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
Keiran S.M. Smalley; Mercedes Lioni; Maurizia Dalla Palma; Min Xiao; Brijal Desai; Suzanne Egyhazi; Johan Hansson; Hong Wu; Alastair J. King; Patricia Van Belle; David E. Elder; Keith T. Flaherty; Meenhard Herlyn; Katherine L. Nathanson
Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis
Asfar Sohail Azmi; Zhiwei Wang; Ravshan Burikhanov; Vivek M. Rangnekar; Guoping Wang; Jianyong Chen; Shaomeng Wang; Fazlul H. Sarkar; Ramzi M. Mohammad
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
Eri Kawata; Eishi Ashihara; Shinya Kimura; Kazumasa Takenaka; Kiyoshi Sato; Ruriko Tanaka; Asumi Yokota; Yuri Kamitsuji; Miki Takeuchi; Junya Kuroda; Fumihiro Tanaka; Toshikazu Yoshikawa; Taira Maekawa
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Charlotte F. McDonagh; Kristine M. Kim; Eileen Turcott; Lindsay L. Brown; Lori Westendorf; Tiffany Feist; Django Sussman; Ivan Stone; Martha Anderson; Jamie Miyamoto; Robert Lyon; Stephen C. Alley; Hans-Peter Gerber; Paul J. Carter
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity
Claudia Valli; Gabriela Paroni; Angela Maria Di Francesco; Riccardo Riccardi; Michele Tavecchio; Eugenio Erba; Andrea Boldetti; Maurizio Gianni'; Maddalena Fratelli; Claudio Pisano; Lucio Merlini; Antonio Antoccia; Chiara Cenciarelli; Mineko Terao; Enrico Garattini
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
Sonya D. Zabludoff; Chun Deng; Michael R. Grondine; Adam M. Sheehy; Susan Ashwell; Benjamin L. Caleb; Stephen Green; Heather R. Haye; Candice L. Horn; James W. Janetka; Dongfang Liu; Elizabeth Mouchet; Shannon Ready; Judith L. Rosenthal; Christophe Queva; Gary K. Schwartz; Karen J. Taylor; Archie N. Tse; Graeme E. Walker; Anne M. White
N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing
Hongtao Wang; Barry J. Maurer; Yong-Yu Liu; Elaine Wang; Jeremy C. Allegood; Samuel Kelly; Holly Symolon; Ying Liu; Alfred H. Merrill,, Jr.; Valérie Gouazé-Andersson; Jing Yuan Yu; Armando E. Giuliano; Myles C. Cabot
A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Julia S. Samaddar; Virgil T. Gaddy; Jennifer Duplantier; Sudharsan Periyasamy Thandavan; Manish Shah; Marlena J. Smith; Darren Browning; Jim Rawson; Sylvia B. Smith; John T. Barrett; Patricia V. Schoenlein
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer
Yoganand Balagurunathan; David L. Morse; Galen Hostetter; Vijayalakshmi Shanmugam; Phillip Stafford; Sonsoles Shack; John Pearson; Maria Trissal; Michael J. Demeure; Daniel D. Von Hoff; Victor J. Hruby; Robert J. Gillies; Haiyong Han
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.